It is just 1/7th of the current Annual Sales CKD patients expenditure on Drugs.
With 400 MLN sales, AFFY gets a cool - 80 MLN $ Royalty payout along with 180 MLN $ milestone payment.
This is almost $2 per share (@5 X royalty valuation - the PPS should be $10) and on top of it add $5 for the milestone payment, which makes it a realistic 14-15 $ per share valuation.
With the Securities Lawsuit diluted to a mere D&O case, there is nothing to worry. I'll add more once I get my WMI TRUST payouts.
Sentiment: Strong Buy
Very educational analysis. Thank you!
I hope you are right Jagan. I really do. But what if the cash runs out before O 's problems are figured out.? !.
And what sales did they achieve before the recall to make you believe about the 400 million sales?!